Immunotherapy for ovarian cancer: what to know

Immunotherapy uses medicines that change immune signals so immune cells can respond to cancer. It may be offered alone or alongside another treatment when the cancer's biology and treatment history make that approach reasonable. Testing can help the team understand tumour characteristics; ask whether genomic tumour profiling or BRCA genetic testing is relevant. Surgery, including ovarian cancer debulking surgery or oophorectomy, may be considered at a different point in care. Immunotherapy is different from chemotherapy, although both can be part of one treatment plan.

Bring a list of medicines, supplements, allergies and existing immune conditions. Tell the oncology team about bowel, lung, liver, kidney or hormone problems before treatment begins. Keep a record of new symptoms between infusions, even if they seem mild. Do not start steroids or stop prescribed medicines without advice, because they can affect immune treatment decisions. Your team may arrange blood tests and scans such as pelvic ultrasound to assess symptoms or treatment planning. Supportive and palliative care can be added at any stage to help with pain, nausea, fatigue, sleep or emotional strain.

Contact your oncology service promptly for new or worsening diarrhoea, severe abdominal pain, yellowing of the skin, marked breathlessness, chest pain, a persistent cough, confusion, severe headache, reduced urine, or a widespread rash. These symptoms can reflect inflammation in an organ and may need assessment before the next dose. Seek urgent help for severe breathing difficulty, fainting, sudden weakness or inability to keep fluids down.

Ask which tumour findings support immunotherapy, what benefit the team is aiming for, how response will be checked, and what alternatives exist. Clarify the planned schedule, common immune-related effects, who to call outside clinic hours, and whether treatment could be paused or changed if inflammation develops.